Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| granulocyte macrophage colony stimulating factor (GM-CSF) types substances | 5025 | 123774-72-1 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
a glycosylated form of recombinant GM-CSF; used to treat drug-induced agranulocytosis; amino acid sequence known
|
| Dose | Unit | Route |
|---|---|---|
| 0.45 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 5, 1991 | FDA | BERLEX LABS |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device related bacteraemia | 42.58 | 31.01 | 7 | 1268 | 412 | 90626760 |
| Pyrexia | 42.39 | 31.01 | 49 | 1226 | 660436 | 89966736 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device related bacteraemia | 48.51 | 25.93 | 10 | 1806 | 669 | 42618850 |
| Hypotension | 37.21 | 25.93 | 50 | 1766 | 257581 | 42361938 |
| Pyrexia | 35.04 | 25.93 | 61 | 1755 | 393981 | 42225538 |
| Pain | 34.55 | 25.93 | 47 | 1769 | 244801 | 42374718 |
| Bone pain | 32.02 | 25.93 | 17 | 1799 | 23775 | 42595744 |
| Chills | 28.66 | 25.93 | 27 | 1789 | 94039 | 42525480 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device related bacteraemia | 91.54 | 26.32 | 17 | 2575 | 1213 | 110585494 |
| Pyrexia | 78.09 | 26.32 | 100 | 2492 | 898165 | 109688542 |
| Hypotension | 66.55 | 26.32 | 71 | 2521 | 523778 | 110062929 |
| Device related infection | 51.90 | 26.32 | 23 | 2569 | 39496 | 110547211 |
| Pain | 42.37 | 26.32 | 78 | 2514 | 954877 | 109631830 |
| Chills | 39.65 | 26.32 | 34 | 2558 | 190546 | 110396161 |
| Device occlusion | 30.60 | 26.32 | 12 | 2580 | 15173 | 110571534 |
| Transaminases abnormal | 27.37 | 26.32 | 6 | 2586 | 982 | 110585725 |
| Hyperhidrosis | 26.54 | 26.32 | 27 | 2565 | 187271 | 110399436 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L03AA09 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Colony stimulating factors |
| FDA CS | M0024695 | Granulocyte-Macrophage Colony-Stimulating Factor |
| FDA CS | M0024696 | Granulocyte Colony-Stimulating Factor |
| FDA PE | N0000009451 | Increased Myeloid Cell Production |
| MeSH PA | D007155 | Immunologic Factors |
| FDA EPC | N0000175666 | Leukocyte Growth Factor |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
| CHEBI has role | CHEBI:64951 | anti-HBV agent |
| CHEBI has role | CHEBI:70868 | antileishmanial agent |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
| CHEBI has role | CHEBI:231911 | renoprotective agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Chemotherapy-induced neutropenia | indication | 425229001 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Granulocyte macrophage colony-stimulating factor receptor | Membrane receptor | AGONIST | Kd | 8.30 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
| ID | Source |
|---|---|
| 5TAA004E22 | UNII |
| D05803 | KEGG_DRUG |
| 4019558 | VUID |
| N0000147658 | NUI |
| 4019558 | VANDF |
| C0216231 | UMLSCUI |
| CHEBI:749544 | CHEBI |
| CHEMBL1201670 | ChEMBL_ID |
| DB00020 | DRUGBANK_ID |
| 6842 | INN_ID |
| C081222 | MESH_SUPPLEMENTAL_RECORD_UI |
| 7905 | IUPHAR_LIGAND_ID |
| 203878 | RXNORM |
| 1744 | MMSL |
| 5443 | MMSL |
| d00513 | MMSL |
| 003580 | NDDF |
| 108967001 | SNOMEDCT_US |
| 388375003 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Leukine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71837-5843 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 250 ug | SUBCUTANEOUS | BLA | 26 sections |